A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
2015 ◽
Vol 51
(4)
◽
pp. 383-388
◽
Antonio Jimeno
◽
Julie E. Bauman
◽
Charles Weissman
◽
Douglas Adkins
◽
Ian Schnadig
◽
...
2015 ◽
Vol 26
(3)
◽
pp. 556-561
◽
A. Jimeno
◽
K. Shirai
◽
M. Choi
◽
J. Laskin
◽
M. Kochenderfer
◽
...
2012 ◽
Vol 118
(20)
◽
pp. 5008-5014
◽
Matthew G. Fury
◽
Nancy Y. Lee
◽
Eric Sherman
◽
Donna Lisa
◽
Katherine Kelly
◽
...
2010 ◽
Vol 117
(4)
◽
pp. 795-801
◽
Matthew G. Fury
◽
Sofia Haque
◽
Hilda Stambuk
◽
Ronglai Shen
◽
Diane Carlson
◽
...
2021 ◽
Vol 115
◽
pp. 105192
Douglas R. Adkins
◽
Jin-Ching Lin
◽
Assuntina Sacco
◽
Jessica Ley
◽
Peter Oppelt
◽
...
2010 ◽
Vol 267
(9)
◽
pp. 1423-1428
◽
Cesare Piazza
◽
Daniela Cocco
◽
Luigi De Benedetto
◽
Francesca Del Bon
◽
Piero Nicolai
◽
...
2011 ◽
Vol 227
(2)
◽
pp. 467-473
◽
Santanu Dasgupta
◽
Rupesh Dash
◽
Swadesh K. Das
◽
Devanand Sarkar
◽
Paul B. Fisher
2013 ◽
Vol 34
(8)
◽
pp. 1632-1636
◽
M. McDermott
◽
M. Hughes
◽
T. Rath
◽
J.T. Johnson
◽
D.E. Heron
◽
...
Hans-Jonas Meyer
◽
Anne Kathrin Höhn
◽
Alexey Surov
2011 ◽
Vol 2011
◽
pp. 18-19
Close
Export Citation Format
Close
Share Document
Close